^
    Back
    Association details:
    Biomarker:ERCC1 overexpression
    Cancer:Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Respir Dis Treat
    Title:

    Predictive Value of ERCC1 Expression on Treatment Response to Cisplatin-Based Regimens in Small Cell Lung Cancer: A Retrospective Analysis

    Excerpt:
    Tumor regression rate was higher in ERCC1 positive patients than those with negative ERCC1 expression (66.7% vs. 27.3%, p=0.036). In conclusion, high expression of ERCC1 was associated with higher response rate to cisplatin-based regimens in patients with SCLC.